No connection

Search Results

ACB vs ANIK

ACB
Aurora Cannabis Inc.
BEARISH
Price
$3.43
Market Cap
$194.5M
Sector
Healthcare
AI Confidence
85%
ANIK
Anika Therapeutics, Inc.
BEARISH
Price
$14.20
Market Cap
$204.8M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ACB
--
ANIK
--
Forward P/E
ACB
-31.18
ANIK
35.5
P/B Ratio
ACB
0.49
ANIK
1.37
P/S Ratio
ACB
0.52
ANIK
1.82
EV/EBITDA
ACB
-6.68
ANIK
-29.07

Profitability

Gross Margin
ACB
36.03%
ANIK
56.56%
Operating Margin
ACB
2.32%
ANIK
2.11%
Profit Margin
ACB
-22.51%
ANIK
-9.64%
ROE
ACB
-15.51%
ANIK
-6.71%
ROA
ACB
-4.36%
ANIK
-3.52%

Growth

Revenue Growth
ACB
6.8%
ANIK
0.0%
Earnings Growth
ACB
-94.7%
ANIK
--

Financial Health

Debt/Equity
ACB
0.18
ANIK
0.18
Current Ratio
ACB
3.06
ANIK
4.72
Quick Ratio
ACB
1.05
ANIK
3.71

Dividends

Dividend Yield
ACB
--
ANIK
--
Payout Ratio
ACB
0.0%
ANIK
0.0%

AI Verdict

ACB BEARISH

Aurora Cannabis Inc. (ACB) exhibits severe financial distress signals, underscored by a Piotroski F-Score of 1/9—indicating extreme weakness in operational and financial health. The absence of an Altman Z-Score and persistent negative profitability metrics (ROE: -15.51%, ROA: -4.36%) suggest high bankruptcy risk, especially given the company's negative earnings and declining cash flow. Despite a low price-to-book (0.49) and price-to-sales (0.52), the stock trades at a significant discount due to deteriorating fundamentals and a 96.9% 5-year decline. The lack of analyst coverage and neutral insider activity further erode confidence in near-term recovery.

Strengths
Low price-to-book ratio (0.49) suggests potential undervaluation on a balance sheet basis
Strong gross margin (36.03%) indicates efficient production and cost control
High current ratio (3.06) reflects strong short-term liquidity
Risks
Piotroski F-Score of 1/9 indicates severe financial distress and poor operational performance
Negative ROE (-15.51%) and ROA (-4.36%) reflect persistent unprofitability
Earnings growth has collapsed by -94.70% YoY, with a -93.60% Q/Q decline
ANIK BEARISH

ANIK's Piotroski F-Score of 2/9 indicates weak financial health, with significant red flags in profitability and cash flow. The company reports negative net income and ROE, despite a strong gross margin of 56.56%, suggesting operational inefficiencies. While the debt-to-equity ratio of 0.18 and high current ratio (4.72) point to solid liquidity, the lack of revenue growth (0% YoY) and absence of free cash flow undermine long-term sustainability. The stock trades at a forward P/E of 35.50, which is elevated relative to its lack of earnings growth, and the 63.8% 6-month rally appears speculative rather than fundamentals-driven. Analysts rate it 'strong_buy' with a target of $17.50, but this is not supported by core financial metrics.

Strengths
High gross margin (56.56%) indicates strong pricing power and cost control in production
Strong liquidity position with current ratio of 4.72 and quick ratio of 3.71
Low debt-to-equity ratio (0.18) suggests conservative capital structure
Risks
Piotroski F-Score of 2/9 signals poor financial health and high distress risk
Negative net profit margin (-9.64%) and ROE (-6.71%) indicate unprofitable operations
Zero revenue growth (0% YoY) despite a growing market cap, suggesting stagnation

Compare Another Pair

ACB vs ANIK: Head-to-Head Comparison

This page compares Aurora Cannabis Inc. (ACB) and Anika Therapeutics, Inc. (ANIK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile